Rising healthcare costs and changing coverage increase financial burdens for individuals with hereditary conditions like ...
During the 2025 American Society of Hematology annual meeting, held earlier this month in Orlando, Florida, CURE sat down ...
Preoperative breast MRI did not improve LRR, DRFR, or OS outcomes in early-stage breast cancer patients. The trial involved ...
High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...
Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior ...
The addition of the immune checkpoint inhibitor Tecentriq (atezolizumab) to neoadjuvant chemotherapy and as a single agent ...
Tukysa (tucatinib) combined with Herceptin (trastuzumab) and Perjeta (pertuzumab) extended progression-free survival as a frontline maintenance approach compared with placebo plus Herceptin and ...
Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or ...
In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.
Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...
“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...
Standard-of-care treatment with Janus kinase inhibitor monotherapy improves splenomegaly and symptom burden but provides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback